Volastra unveils first human data of its solid tumor drug target
Volastra Therapeutics has been bullish about KIF18A as a solid tumor drug target.
And now, more than five years after launch, the company is reporting …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
